PE20220809A1 - Anticuerpos anti-angpt2 - Google Patents
Anticuerpos anti-angpt2Info
- Publication number
- PE20220809A1 PE20220809A1 PE2021002220A PE2021002220A PE20220809A1 PE 20220809 A1 PE20220809 A1 PE 20220809A1 PE 2021002220 A PE2021002220 A PE 2021002220A PE 2021002220 A PE2021002220 A PE 2021002220A PE 20220809 A1 PE20220809 A1 PE 20220809A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- amino acid
- acid sequence
- cdr1
- cdr2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Referido a un anticuerpo neutralizantes antiangiopoyetina 2 anti-ANGPT2 o un fragmento de fijacion al antigeno que comprende: una region variable de la cadena pesada que comprende la secuencia de aminoacidos de SEQ ID NO: 13 (H-CDR1); la secuencia de aminoacidos de SEQ ID NO: 15 (H-CDR2); y la secuencia de aminoacidos de SEQ ID NO: 17 (H-CDR3), y una region variable de la cadena liviana que comprende la secuencia de aminoacidos de SEQ ID NO: 19 (L-CDR1); la secuencia de aminoacidos de SEQ ID NO: 22 (L-CDR2); y la secuencia de aminoacidos de SEQ ID NO: 24 (L-CDR3), o una region variable de la cadena pesada que comprende la secuencia de aminoacidos de SEQ ID NO: 14 (H-CDR1); la secuencia de aminoacidos de SEQ ID NO: 15 (H-CDR2); y la secuencia de aminoacidos de SEQ ID NO: 17 (H-CDR3); y una region variable de la cadena liviana que comprende la secuencia de aminoacidos de SEQ ID NO: 19 (L-CDR1); la secuencia de aminoacidos de SEQ ID NO: 22 (L-CDR2); y la secuencia de aminoacidos de SEQ ID NO: 24 (L-CDR3), entre otras. Tambien se refiere a una composicion farmaceutica que comprende dicho anticuerpo o fragmento de fijacion al antigeno y un portador aceptable desde farmaceuticamente aceptable, y su uso en el tratamiento de enfermedades como hipertrofia cardiaca, lesion isquemica por revascularizacion, entre otros.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962867253P | 2019-06-27 | 2019-06-27 | |
| US202063013022P | 2020-04-21 | 2020-04-21 | |
| PCT/US2020/039477 WO2020264065A1 (en) | 2019-06-27 | 2020-06-25 | Anti-angpt2 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220809A1 true PE20220809A1 (es) | 2022-05-20 |
Family
ID=71662321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021002220A PE20220809A1 (es) | 2019-06-27 | 2020-06-25 | Anticuerpos anti-angpt2 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11396539B2 (es) |
| EP (1) | EP3990489A1 (es) |
| JP (1) | JP7649756B2 (es) |
| KR (1) | KR20220028032A (es) |
| CN (1) | CN114080396B (es) |
| AU (1) | AU2020308569A1 (es) |
| BR (1) | BR112021024176A2 (es) |
| CA (1) | CA3140071A1 (es) |
| CL (1) | CL2021003367A1 (es) |
| CO (1) | CO2021017414A2 (es) |
| CR (1) | CR20210683A (es) |
| EC (1) | ECSP22004680A (es) |
| IL (1) | IL289160A (es) |
| JO (1) | JOP20210339A1 (es) |
| MA (1) | MA56394A (es) |
| MX (1) | MX2021015743A (es) |
| PE (1) | PE20220809A1 (es) |
| PH (1) | PH12021553117A1 (es) |
| SA (1) | SA521431223B1 (es) |
| TW (1) | TWI877179B (es) |
| WO (1) | WO2020264065A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI877179B (zh) * | 2019-06-27 | 2025-03-21 | 德商百靈佳殷格翰國際股份有限公司 | 抗-angpt2抗體 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE266710C (es) | ||||
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4434173A (en) | 1982-08-23 | 1984-02-28 | Pfizer Inc. | Bis-esters of 4,5-di(hydroxymethyl)-2-oxo-1,3-dioxole as antibacterial agents |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| US6455035B1 (en) * | 1999-03-26 | 2002-09-24 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
| CN105085678B (zh) * | 2004-12-21 | 2019-05-07 | 阿斯利康公司 | 血管生成素-2的抗体及其应用 |
| RU2509085C2 (ru) | 2008-01-28 | 2014-03-10 | Медиммун Лимитед | Стабилизированные антитела против ангиопоэтина-2 и их применение |
| US8133979B2 (en) | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US20110227286A1 (en) * | 2010-03-18 | 2011-09-22 | Davies Janet L | Board Game and Method of Playing the Same |
| US9575073B2 (en) * | 2011-10-10 | 2017-02-21 | Rutgers, The State University Of New Jersey | Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma |
| US20150044227A1 (en) * | 2012-03-08 | 2015-02-12 | Medimmune, Llc | Methods of treatment with angiopoietin-2 antibodies |
| US9902767B2 (en) * | 2013-07-29 | 2018-02-27 | Samsung Electronics Co., Ltd. | Method of blocking vascular leakage using an anti-ANG2 antibody |
| AU2014368695A1 (en) | 2013-12-20 | 2016-04-14 | F. Hoffmann-La Roche Ag | Combination therapy with an anti-ANG2 antibody and a CD40 agonist |
| AR100270A1 (es) * | 2014-05-19 | 2016-09-21 | Lilly Co Eli | Anticuerpos ang2 |
| SG11201703237VA (en) * | 2014-11-19 | 2017-06-29 | Axon Neuroscience Se | Humanized tau antibodies in alzheimer's disease |
| AU2017204139B2 (en) | 2016-06-17 | 2018-08-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for the depletion of cells |
| US11485775B2 (en) * | 2016-10-21 | 2022-11-01 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
| IL273592B2 (en) * | 2017-09-29 | 2025-11-01 | Chugai Pharmaceutical Co Ltd | Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient |
| TWI877179B (zh) * | 2019-06-27 | 2025-03-21 | 德商百靈佳殷格翰國際股份有限公司 | 抗-angpt2抗體 |
-
2020
- 2020-06-24 TW TW109121573A patent/TWI877179B/zh active
- 2020-06-25 JO JOP/2021/0339A patent/JOP20210339A1/ar unknown
- 2020-06-25 MA MA056394A patent/MA56394A/fr unknown
- 2020-06-25 BR BR112021024176A patent/BR112021024176A2/pt unknown
- 2020-06-25 JP JP2021576151A patent/JP7649756B2/ja active Active
- 2020-06-25 CA CA3140071A patent/CA3140071A1/en active Pending
- 2020-06-25 KR KR1020227003085A patent/KR20220028032A/ko active Pending
- 2020-06-25 PH PH1/2021/553117A patent/PH12021553117A1/en unknown
- 2020-06-25 CN CN202080047312.1A patent/CN114080396B/zh active Active
- 2020-06-25 EP EP20742550.5A patent/EP3990489A1/en active Pending
- 2020-06-25 US US16/911,419 patent/US11396539B2/en active Active
- 2020-06-25 WO PCT/US2020/039477 patent/WO2020264065A1/en not_active Ceased
- 2020-06-25 PE PE2021002220A patent/PE20220809A1/es unknown
- 2020-06-25 CR CR20210683A patent/CR20210683A/es unknown
- 2020-06-25 MX MX2021015743A patent/MX2021015743A/es unknown
- 2020-06-25 AU AU2020308569A patent/AU2020308569A1/en not_active Abandoned
-
2021
- 2021-12-16 CL CL2021003367A patent/CL2021003367A1/es unknown
- 2021-12-17 CO CONC2021/0017414A patent/CO2021017414A2/es unknown
- 2021-12-20 IL IL289160A patent/IL289160A/en unknown
- 2021-12-27 SA SA521431223A patent/SA521431223B1/ar unknown
-
2022
- 2022-01-19 EC ECSENADI20224680A patent/ECSP22004680A/es unknown
- 2022-06-17 US US17/842,904 patent/US20220363743A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TWI877179B (zh) | 2025-03-21 |
| US11396539B2 (en) | 2022-07-26 |
| TW202115112A (zh) | 2021-04-16 |
| JP2022538062A (ja) | 2022-08-31 |
| WO2020264065A1 (en) | 2020-12-30 |
| ECSP22004680A (es) | 2022-02-25 |
| MA56394A (fr) | 2022-05-04 |
| CL2021003367A1 (es) | 2022-10-07 |
| CA3140071A1 (en) | 2020-12-30 |
| US20220363743A1 (en) | 2022-11-17 |
| KR20220028032A (ko) | 2022-03-08 |
| SA521431223B1 (ar) | 2024-04-21 |
| US20200407435A1 (en) | 2020-12-31 |
| PH12021553117A1 (en) | 2022-07-25 |
| CN114080396B (zh) | 2024-05-17 |
| IL289160A (en) | 2022-02-01 |
| JOP20210339A1 (ar) | 2023-01-30 |
| EP3990489A1 (en) | 2022-05-04 |
| AU2020308569A1 (en) | 2021-12-02 |
| BR112021024176A2 (pt) | 2022-03-22 |
| MX2021015743A (es) | 2022-01-27 |
| CO2021017414A2 (es) | 2022-01-17 |
| CR20210683A (es) | 2022-02-23 |
| CN114080396A (zh) | 2022-02-22 |
| JP7649756B2 (ja) | 2025-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082916A1 (es) | Moleculas de union a 4-1bb | |
| PE20142041A1 (es) | Anticuerpos anti-il-36r | |
| PE20080036A1 (es) | Anticuerpos humanos para la interleucina-13 (il13) | |
| PE20220708A1 (es) | Anticuerpos anti-cd73 | |
| CO2020014727A2 (es) | Anticuerpo anti proteína reguladora de señales alfa sirpαlfa | |
| AR103868A1 (es) | Anticuerpos anti-cd47 como agentes terapéuticos | |
| PE20071055A1 (es) | Anticuerpos anti mn | |
| EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
| AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
| AR108663A1 (es) | ANTICUERPOS CONTRA a-SINUCLEÍNA Y SUS USOS | |
| NZ744185A (en) | Antibodies and conjugates thereof | |
| AR109715A1 (es) | Anticuerpos anti-cd27 | |
| RU2014108047A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы | |
| PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| RU2019122802A (ru) | Конъюганты связующего и активного вещества (adc), имеющие ферментативно расщепляемые группы | |
| MX2009009226A (es) | Anticuerpos recombinantes para el tratamiento de infecciones con el virus respiratorio sincitial. | |
| PE20200173A1 (es) | Anticuerpos anti-trkb | |
| AR101202A1 (es) | Anticuerpo anti-tie2 humana | |
| PE20220287A1 (es) | Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares | |
| CO2018001010A2 (es) | Anticuerpos monoclonales específicos para el antígeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por vrsh | |
| AR123671A1 (es) | Anticuerpo fn14 anti-humano | |
| PE20231076A1 (es) | Anticuerpos anti-pd-1 | |
| PE20220516A1 (es) | ANTICUERPO BIESPECIFICO CONTRA (alfa)-SYN/IGF1R Y USO DEL MISMO | |
| PE20220809A1 (es) | Anticuerpos anti-angpt2 | |
| AR077941A1 (es) | Anticuerpos contra osteopontina |